Takeda』s Dengue Vaccine Candidate Associated with Reduced Incidence of Dengue in Children and Adolescents; New 18-Month Interim Phase 2 Data Published in The Lancet Infectious Diseases
Trial assesses safety and immunogenicity of different schedules of TAK-003 dengue vaccine candidate in children and adolescents ages 2 through 17 living in dengue-endemic areas1 Children a......